Dr. Jonathan K. Freeman, MD
Pathology (Anatomic Pathology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 261
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Anatomic Pathology Physician primary
MA license 79989
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 261
- Services billed
- 1,255
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 594 | 316 |
| Special stained specimen slides to examine tissue, each additional procedure | 427 | 87 |
| Special stained specimen slides to examine tissue including interpretation and report | 271 | 108 |
| Special stained specimen slides to examine tissue, initial procedure | 166 | 132 |
| Antibody evaluation, each additional single antibody stain procedure | 136 | 17 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 120 | 110 |
| Preparation of tissue for examination by removing any calcium present | 92 | 88 |
| Bone marrow, smear interpretation | 76 | 73 |
| Genetic sequencing localization, initial procedure | 34 | 29 |
| Microscopic genetic analysis of tumor, manual | 30 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $45.08 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $45.08 |
|---|
| Food and Beverage | $45.08 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.